David Campbell is an innovative Associate Principal Scientist specializing in T Cell Engagers, drawing on over 25 years of experience in research and development within academic and biotech sectors. Currently at AstraZeneca, they lead the preclinical in vivo cancer vaccine platform technologies, focusing on experimental design and execution of cancer immunotherapy studies. Previously, David held positions at LigoCyte Pharmaceuticals and Immune Design Corp., where they contributed to vaccine development and assay processes. David’s educational background includes a BS in Environmental and Forest Biology from SUNY College of Environmental Science and Forestry.
This person is not in the org chart
This person is not in any teams
This person is not in any offices